{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "83-year-old male admitted on October 30, 2019, with cough, expectoration, and hemoptysis for 1 week. History of tuberculosis for more than 30 years, chronic bronchitis, and emphysema for 10 years.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "69860004",
              "label": "Pulmonary tuberculosis",
              "status": "historical",
              "onset_date": null
            },
            {
              "code": "10744005",
              "label": "Chronic bronchitis",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "87433001",
              "label": "Emphysema",
              "status": "active",
              "onset_date": null
            }
          ],
          "HPI": [
            {
              "summary": "Cough, expectoration, and hemoptysis for 1 week",
              "duration": "1 week",
              "onset": null,
              "progression": "unknown",
              "associated_symptoms": [],
              "alleviating_factors": [],
              "exacerbating_factors": []
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Chest CT revealed an irregular mass (5.3\u00d72.6 cm) in the upper lobe of the left lung. PET/CT showed multiple lymph node and bone metastases.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Mass",
              "body_part": "Upper lobe of the left lung",
              "modality": "CT",
              "finding": "Irregular mass (5.3\u00d72.6 cm)",
              "date": null
            },
            {
              "type": "Metastasis",
              "body_part": "Lymph node",
              "modality": "PET/CT",
              "finding": "Multiple lymph node metastases",
              "date": null
            },
            {
              "type": "Metastasis",
              "body_part": "Bone",
              "modality": "PET/CT",
              "finding": "Bone metastases",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Transthoracic core needle biopsy of the lung mass showed tumor cell characteristics with adenoid and stratified structures and visible nuclear division. Immunohistochemistry: TTF-1, CK7, SPA, napsin-A and Ki-67 (10%) positive; villin, P63 and P40 negative. Diagnosed with stage IV (T4aN2M1) invasive lung adenocarcinoma.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Needle biopsy",
              "body_part": "Lung",
              "modality": "other",
              "finding": "Lung mass",
              "date": null
            }
          ],
          "diagnoses": [
            {
              "code": "C34",
              "label": "Lung cancer",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C34.9",
              "label": "Lung adenocarcinoma",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "On December 6, 2019, NGS identified a novel PTH2R-ALK fusion in the patient\u2019s tumor tissue, composed of exon 1 of PTH2R gene and exon 20\u201329 of ALK gene. Fluorescence in situ hybridization confirmed ALK positivity.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0086582",
              "label": "Tumor",
              "status": "active",
              "onset_date": "2019-12-06"
            }
          ],
          "labs": [
            {
              "test": "Next Generation Sequencing",
              "value": "PTH2R-ALK fusion",
              "timestamp": "2019-12-06"
            },
            {
              "test": "Fluorescence in situ hybridization",
              "value": "ALK positivity",
              "timestamp": "2019-12-06"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Patient started oral crizotinib 250 mg BID from December 12, 2019. After 10 days, the patient developed mild nausea without vomiting.",
        "clinical_data": {
          "medications": [
            {
              "drug": "Crizotinib",
              "dosage": "250 mg",
              "frequency": "BID",
              "modality": "oral",
              "start_date": "2019-12-12",
              "end_date": null
            }
          ],
          "HPI": [
            {
              "summary": "Patient developed mild nausea without vomiting after starting crizotinib.",
              "onset": "2019-12-22",
              "progression": "sudden",
              "associated_symptoms": [
                "Nausea"
              ]
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Liver function reexamination revealed elevated ALT and AST levels (3-4 times higher than baseline), indicating mild liver function impairment. Treated with polyene phosphatidylcholine for liver protection.",
        "timestamp": "2020",
        "clinical_data": {
          "labs": [
            {
              "test": "Alanine Aminotransferase Measurement",
              "value": "3-4 times higher than baseline",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "Aspartate Aminotransferase Measurement",
              "value": "3-4 times higher than baseline",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ],
          "diagnoses": [
            {
              "code": "C0023892",
              "label": "Liver Function Impairment",
              "status": "active",
              "onset_date": null
            }
          ],
          "medications": [
            {
              "drug": "Polyene phosphatidylcholine",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "Liver protection"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Follow-up CT on January 18, 2020, showed the left lung mass decreased to 1.47x0.89 cm, indicating a partial response to treatment.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Lung mass",
              "body_part": "Left lung",
              "modality": "CT",
              "finding": "Decreased to 1.47x0.89 cm",
              "impression": "Partial response to treatment",
              "date": "2020-01-18"
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "NGS results showed PTH2R-ALK fusion breakpoint.",
        "clinical_data": {
          "labs": [
            {
              "test": "Next Generation Sequencing",
              "value": "PTH2R-ALK fusion breakpoint",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "Fluorescence in situ hybridization (FISH) image showed a split signal with a frequency of 25% (400x magnification).",
        "clinical_data": {
          "imaging": [
            {
              "type": "Fluorescence in situ hybridization",
              "modality": "other",
              "finding": "split signal with a frequency of 25%",
              "impression": "split signal with a frequency of 25%"
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 9,
        "content": "Liver Function Tests Before Crizotinib Treatment: ALT 14.0 U/L, AST 16.0 U/L, \u03b3-GT 18.0 U/L, ALP 71.0 U/L, LDH 150.0 U/L, TBIL 29.7 \u03bcmol/L.",
        "clinical_data": {
          "labs": [
            {
              "test": "Alanine Aminotransferase Measurement",
              "value": "14.0",
              "unit": "U/L",
              "timestamp": null
            },
            {
              "test": "Aspartate Aminotransferase Measurement",
              "value": "16.0",
              "unit": "U/L",
              "timestamp": null
            },
            {
              "test": "Gamma-Glutamyl Transferase Measurement",
              "value": "18.0",
              "unit": "U/L",
              "timestamp": null
            },
            {
              "test": "Alkaline Phosphatase Measurement",
              "value": "71.0",
              "unit": "U/L",
              "timestamp": null
            },
            {
              "test": "Lactate Dehydrogenase Measurement",
              "value": "150.0",
              "unit": "U/L",
              "timestamp": null
            },
            {
              "test": "Total Bilirubin Measurement",
              "value": "29.7",
              "unit": "\u03bcmol/L",
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N11",
      "label": "Step 11",
      "customData": {
        "node_id": "K",
        "node_step_index": 10,
        "content": "Liver Function Tests After Crizotinib Treatment: ALT 205.0 U/L, AST 114.0 U/L, \u03b3-GT 69.0 U/L, ALP 105.0 U/L, LDH 389.0 U/L, TBIL 7.1 \u03bcmol/L.",
        "clinical_data": {
          "labs": [
            {
              "test": "Alanine Aminotransferase Measurement",
              "value": "205.0",
              "unit": "U/L",
              "flag": "abnormal"
            },
            {
              "test": "Aspartate Aminotransferase Measurement",
              "value": "114.0",
              "unit": "U/L",
              "flag": "abnormal"
            },
            {
              "test": "Gamma-Glutamyl Transferase Measurement",
              "value": "69.0",
              "unit": "U/L",
              "flag": "abnormal"
            },
            {
              "test": "Alkaline Phosphatase Measurement",
              "value": "105.0",
              "unit": "U/L",
              "flag": "normal"
            },
            {
              "test": "Lactate Dehydrogenase Measurement",
              "value": "389.0",
              "unit": "U/L",
              "flag": "abnormal"
            },
            {
              "test": "Total Bilirubin",
              "value": "7.1",
              "unit": "\u03bcmol/L",
              "flag": "normal"
            }
          ],
          "medications": [
            {
              "drug": "Crizotinib",
              "indication": "cancer"
            }
          ]
        }
      }
    },
    {
      "id": "N12",
      "label": "Step 12",
      "customData": {
        "node_id": "L",
        "node_step_index": 11,
        "content": "Patient switched to alectinib 1200 mg BID due to intolerable hepatotoxicity.",
        "timestamp": "2020-01-20",
        "clinical_data": {
          "medications": [
            {
              "drug": "alectinib",
              "dosage": "1200 mg BID",
              "frequency": null,
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N13",
      "label": "Step 13",
      "customData": {
        "node_id": "M",
        "node_step_index": 12,
        "content": "Alectinib dosage reduced to 600 mg BID after 1 week due to swelling in legs and fatigue. Symptoms slightly eased with spironolactone.",
        "timestamp": "2020-01-27",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1697599",
              "dosage": "600 mg",
              "frequency": "BID",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0037940",
              "dosage": null,
              "frequency": null,
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": "C0013404"
            }
          ],
          "HPI": [
            {
              "summary": "Swelling in legs and fatigue",
              "duration": "1 week",
              "onset": null,
              "progression": null,
              "associated_symptoms": [
                "C0015967",
                "C0015672"
              ],
              "alleviating_factors": [
                "C0037940"
              ],
              "exacerbating_factors": []
            }
          ]
        }
      }
    },
    {
      "id": "N14",
      "label": "Step 14",
      "customData": {
        "node_id": "N",
        "node_step_index": 13,
        "content": "Carcinoembryonic antigen decreased after one month of",
        "clinical_data": {}
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient's condition progressed from initial symptoms to the discovery of a lung mass and metastases.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0010200",
            "C0015967",
            "C0019058"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Biopsy of the lung mass confirmed invasive lung adenocarcinoma.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [
            "C0005683",
            "C0024144"
          ],
          "change_type": "addition",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "NGS identified a novel PTH2R-ALK fusion in the patient\u2019s tumor tissue, confirmed by FISH.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [],
          "change_type": "addition",
          "target_domain": "diagnosis",
          "timestamp": "2019-12-06"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Patient started oral crizotinib 250 mg BID from December 12, 2019 and developed mild nausea without vomiting after 10 days.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0887513"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2019-12-12"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Liver function reexamination revealed elevated ALT and AST levels, indicating mild liver function impairment. Treated with polyene phosphatidylcholine for liver protection.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "C0151747",
            "C0151737"
          ],
          "change_type": "progression",
          "target_domain": "lab"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Follow-up CT showed the left lung mass decreased to 1.47x0.89 cm, indicating a partial response to treatment.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "resolution",
          "target_domain": "imaging",
          "timestamp": "2020-01-18"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "NGS results showed PTH2R-ALK fusion breakpoint.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [],
          "change_type": "other",
          "target_domain": "lab"
        }
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Fluorescence in situ hybridization (FISH) image showed a split signal with a frequency of 25% (400x magnification).",
        "transition_event": ""
      }
    }
  ]
}